by Lori Solomon The U.S. Food and Drug Administration has approved UCB’s Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa. Bimzelx becomes the first and only approved medicine designed to selectively inhibit interleukin 17F in addition to interleukin 17A and is the fifth indication for Bimzelx in the United States. The approval is supported...
Tag: <span>hidradenitis suppurativa</span>
Post
Hidradenitis Suppurativa Symptoms Eased by Semaglutide-Aided Weight Loss
People with hidradenitis suppurativa (HS) who have overweight or obesity may benefit from adjunctive treatment with the glucagon-like peptide 1 (GLP-1) receptor agonist semaglutide (Ozempic, Wegovy), suggests research presented at the annual meeting of the European Academy of Dermatology and Venereology (EADV). In a small, nonrandomized, observational, retrospective study, semaglutide-aided weight loss was found to...
Post
Researchers discover genetic locations for increased risk of hidradenitis suppurativa
by Kendall Daniels, University of North Carolina at Chapel Hill School of Medicine Histologic image of hidradenitis suppurativa. Credit: University of North Carolina at Chapel Hill School of Medicine University of North Carolina at Chapel Hill (UNC) School of Medicine researchers Christopher Sayed, MD, Yun Li, Ph.D., and Karen Mohlke, Ph.D., discovered the genomic locations that contribute to...